What Zejula Treats: Main Uses and Benefits

Zejula is indicated for the supportive management of advanced high-grade epithelial cancer originating in the ovaries, fallopian tubes, or peritoneum. The medication is applied across domains where additional symptomatic support is needed, which may support the management of the disease state and may assist with maintaining functional stability.

Zejula is specifically applied in the maintenance setting, following a favorable response (partial or complete) to prior platinum-based chemotherapy. The use of Zejula is guided by tumor characteristics, making it relevant for patients whose cancer is either Homologous Recombination Deficiency (HRD)-positive or carries a BRCA gene mutation. Its application is relevant across domains where additional symptomatic support is needed in this specific patient group.

“This approach is considered relevant when supportive symptom management is appropriate and may contribute to improved comfort during periods of disease stability.”

This continuous therapeutic support is relevant for conditions characterized by an underlying risk of recurrence, helping to maintain a sense of stability when symptoms are less noticeable.

Quick Fact: Supportive Management for Recurrence Risk

The primary therapeutic purpose plays a role in managing symptoms related to the progression risk and its associated symptoms, offering support that helps ease the overall symptom burden by supporting the general well-being during symptomatic phases.

Regulatory References

1. European Medicines Agency (EMA) EPAR Product Information

Official Eligibility and Contraindications for Zejula (Niraparib)

Official regulatory documents define the specific populations allowed to use Zejula, as well as those who are formally contraindicated or require restricted use.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult female patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to prior platinum-based chemotherapy (EMA, FDA).
Populations for whom use is contraindicated	Patients with known hypersensitivity to niraparib or any excipients; Breastfeeding women (EMA, FDA, Health Canada).
Populations for whom use is not recommended	Pediatric patients (under 18 years); Patients with Severe Hepatic Impairment or Severe Renal Impairment (EMA, Health Canada).
Age-related eligibility rules	Use is generally not recommended for the pediatric population as safety and efficacy have not been established. No overall dose adjustment is required for geriatric patients (ge 65 years old) (EMA, FDA).
Condition-specific eligibility rules	Pregnancy is a state of non-eligibility; females of reproductive potential must use effective contraception during and after treatment. A confirmed diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) requires permanent discontinuation (EMA, FDA).

The official eligibility profile is strictly defined by these criteria, restricting use to a specific adult patient population that meets precise disease and treatment history requirements. Absolute non-eligibility is confirmed by the formal contraindications and the requirement to discontinue for specific secondary blood malignancies.

Zejula Interactions with other medicines and products

The official regulatory profile for niraparib (Zejula) establishes its interaction landscape based on its metabolic pathway, pharmacodynamic risk factors, and specific constraints in certain populations.

Interaction Scope and Constraints

Category	Official Regulatory Statement
Pharmacodynamic Risk	Co-administration with anticoagulation or antiplatelet medicinal products is noted as an additive risk factor for bleeding and hemorrhage due to the potential for drug-induced thrombocytopenia.
Metabolic Pathway	Niraparib is metabolized primarily by carboxylesterases, not by major Cytochrome P450 (CYP) enzymes. This classification implies no clinically significant drug interactions are expected with CYP enzyme inhibitors or inducers.
Drug-Food Interaction	Co-administration with a high-fat, high-calorie meal causes a documented 22% decrease in the drug’s maximum plasma concentration (C max). However, the overall systemic exposure (AUC) is not significantly affected.

Population and Restriction Notes

• Hepatic Impairment: Patients with moderate or severe hepatic impairment represent a population with altered clearance; official labeling requires a starting dosage adjustment to manage potential increases in exposure.
• Contraindicated Combination: Breastfeeding is formally contraindicated during treatment and for a period of one month after the final dose of niraparib.

The regulatory documents define the product’s interaction structure by minimizing the risk of pharmacokinetic drug–drug interactions due to non-CYP metabolism, while simultaneously identifying necessary risk management for pharmacodynamic effects and specific exposure constraints in hepatic impairment and with food.

How Zejula Works

The action of niraparib (Zejula) is based on two primary, complementary mechanisms that target the cell's ability to repair its own DNA, resulting in a highly selective cytotoxic effect rooted in the principle of synthetic lethality.

---

Inhibiting DNA Repair Enzymes

The molecule acts as a competitive inhibitor of the DNA repair enzymes Poly(ADP-ribose) polymerase 1 ( PARP-1) and PARP-2. By binding tightly to the PARP enzyme, the drug blocks the first critical step of the Base Excision Repair ( BER) pathway, preventing the PARP enzymes from initiating the repair of minor damage to the cell's genetic code.

---

PARP Trapping and Significant Mechanistic Consequence

A secondary, significant mechanistic consequence is known as PARP trapping, where niraparib stabilizes the PARP-DNA complex onto the site of the DNA lesion. This complex acts as a physical barrier, causing the cell's replication machinery to stall and collapse, converting small, repairable breaks into overwhelming Double-Strand Breaks ( DSBs).

---

Activating Synthetic Lethality

The failure of the PARP-mediated repair mechanism, combined with a pre-existing deficiency in the cell's backup system (Homologous Recombination Repair, or HRR), creates an unrepairable buildup of DSBs. This forces the compromised cell into a self-destruction sequence known as apoptosis, a mechanism culminating in the programmed self-destruction of vulnerable cells.

How to Use Zejula: Official Administration Protocol

Niraparib (Zejula) is an orally administered antineoplastic agent with specific dosing and scheduling requirements. The medicine is available as hard capsules and tablets in various strengths. The dosage form must be swallowed whole, without being chewed, crushed, or split. Administration is a once-daily regimen, taken at approximately the same time each day, and may be taken irrespective of meals.

Dosing and Frequency

The initial daily dose for first-line maintenance is determined by the patient's baseline physical measurements. A dose of 300 mg once daily is used for patients who meet both criteria of weighing >= 77 kg and having a platelet count >= 150,000/mu L. Patients who fall below either threshold are prescribed a starting dose of 200 mg once daily. For the recurrent maintenance indication, the initial dose is 300 mg once daily.

For patients with moderate hepatic impairment, the starting dose is 200 mg once daily. No dosage adjustment is specified for mild-to-moderate renal impairment.

Course and Handling

Treatment is continuous until evidence of disease progression or the need for permanent discontinuation is established. For first-line use, treatment must be initiated no later than 12 weeks after the last platinum-containing regimen. If a dose is missed, it should be skipped, and the next dose should be taken at its regularly scheduled time; no additional dose should be taken to compensate. Treatment must be discontinued if a reduction below 100 mg daily is required.

Overview of Research Evidence for Zejula

This section summarizes the main clinical trials and scientific data that form the basis for the use of niraparib (Zejula), focusing on study types, populations, and measured outcomes as reported by regulatory and peer-reviewed sources. The research provides context for its use as a continuous supportive treatment.

---

Research Examining Use in First-Line Maintenance Treatment

The core research examining the use of niraparib following initial chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal cancer comes from large, randomized, double-blind, placebo-controlled Phase III clinical trials. Patients who responded to initial chemotherapy were observed over defined time intervals.

The primary focus was to evaluate Progression-Free Survival (PFS), which measures the time a patient lives without the disease worsening. Measurements of time until progression were reported to differ between the niraparib group and the placebo group. This finding describes the largest difference observed in the population whose tumors were identified as Homologous Recombination Deficiency (HRD)-positive.

However, data are still emerging for the long-term measure of Overall Survival (OS). The final analyses on OS were monitored, with the data indicating that definitive conclusions on lifespan are still pending or inconclusive in the total study population.

---

Research Examining Use in Recurrent Maintenance Treatment

The research for the recurrent setting is derived from a pivotal randomized, double-blind, placebo-controlled Phase III clinical trial. The studies evaluated PFS in cohorts based on germline BRCA gene mutation (gBRCAm) status. Measurements of time until progression or death were reported to differ between the niraparib group and the placebo group in both cohorts. Research also examined patient-reported outcomes, such as Time Without Symptoms or Toxicity (TWiST).

Data show patterns related to the largest reported differences being observed in patients with a gBRCA mutation. The measured difference in PFS was less pronounced or uncertain in the HRD-negative or non-gBRCAm populations. Comparative evidence is lacking from large head-to-head trials. Research is ongoing in this field to address these areas of uncertainty.

Key Studies & References

1. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (Final OS Analysis)
2. Niraparib Efficacy and Safety in Patients with BRCA-Mutated Ovarian Cancer from 3 Phase 3 Trials (Pooled PRIMA, NOVA, NORA analysis)

Common questions about Zejula (FAQ)

Q: What is Zejula (niraparib) used for?

A: Zejula (niraparib) is a type of medicine called a poly(ADP-ribose) polymerase (PARP) inhibitor. It is used for certain kinds of ovarian, fallopian tube, or primary peritoneal cancer in adults. It can be used to treat advanced disease or to help prevent the cancer from returning after chemotherapy. The specific use depends on your cancer's characteristics, such as whether it has a BRCA gene mutation.

Q: How does Zejula work?

A: Zejula works by blocking the action of PARP proteins, which are involved in repairing damaged DNA inside cancer cells. By inhibiting PARP, Zejula prevents cancer cells from effectively repairing themselves, leading to the death of the cancer cells. This mechanism is particularly effective in cancers that already have trouble with DNA repair, such as those with BRCA gene mutations.

Q: How is Zejula taken?

A: Zejula is an oral medicine taken by mouth as a capsule. The typical dose is taken once daily at around the same time each day. It can be taken with or without food. Your doctor will determine the correct starting dose and may adjust it based on how your body responds and any side effects you experience. It's important to swallow the capsule whole and not to chew, crush, or open it.

Q: What are the common side effects of Zejula?

A: The most common side effects of Zejula often include:

• Low blood cell counts (anemia, thrombocytopenia, neutropenia), which your doctor will monitor with blood tests.
• Fatigue or feeling very tired.
• Nausea and vomiting.
• Constipation or diarrhea.
• Abdominal (stomach) pain.
• Decreased appetite.
• Headache.
• Insomnia (difficulty sleeping).

Q: Can Zejula affect my blood counts?

A: Yes, Zejula can commonly cause a decrease in blood cell counts, which is known as myelosuppression. This includes:

• Anemia (low red blood cells).
• Thrombocytopenia (low platelets).
• Neutropenia (low white blood cells).

Your doctor will perform regular blood tests before and during treatment to check your counts. You should report any symptoms of low blood counts, such as unusual bleeding or bruising, fever, or excessive tiredness, to your healthcare provider immediately.

Q: What serious side effects should I watch for?

A: While less common, serious side effects can occur. These may include:

• Severe blood-related problems (as mentioned above).
• Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML), types of blood cancer that have been reported rarely.
• High blood pressure (hypertension), which should be monitored regularly.
• Posterior Reversible Encephalopathy Syndrome (PRES), a rare neurological condition. You should contact your doctor if you experience sudden severe headache, confusion, seizures, or vision changes.

Storage and Disposal Requirements for Zejula

Official regulatory documents define strict conditions for storing and disposing of Zejula (niraparib) tablets to ensure product integrity and safety.

Scope Detail	Regulatory Requirement
Storage Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Excursions permitted between 15 C to 30 C [1.1, 1.2].
Protection and Packaging	Tablets must be kept in the original container and protected from heat, moisture, and light. The product must not be frozen [1.1, 2.1].
Child Safety	Zejula must be stored out of the reach of children and pets at all times [2.2].
Disposal Instructions	Unused or expired medication must not be flushed down a toilet or placed in household trash. Disposal must be handled by consulting a pharmacist and following local pharmaceutical waste regulations [2.2, 2.3].

These constraints define how the medicine must be preserved and discarded, ensuring the product's quality is maintained over its labeled shelf-life.